Analyzing...
Sir, in the sec was shipped o Sorry, you're
So we were s they were shi the third quart You are not a Sir, I just req Equirus. Pleas So sir, we hav see this busin about it? that coming fe And how big About 52%. Sir, somewhe almost INR75 In spite of th year. Are we calling So 2 Zerodol country. Right. So are forward as we
Fe Page 17 of 19 end, sir? th Ipca and Unichem put together, it's around 3%, 3.25% kind o to move to around 4%. you.
The next question is from the line of Harsh Bhatia from Bandh ead. cond quarter, you had mentioned that there was some U.S. sales out, but not booked. Have we booked those sales this quarter? not audible now, Harsh. What was your question? saying that there were some U.S. sales in second quarter that pped out, but not booked in the second quarter. Those sales hav ter? audible. quest you to rejoin, please. The next question is from the lin se go ahead. ve done phenomenally well in the past years in domestic busine ness behaving as compared to IPM in the at least next 2, 3 year ess, whatever our growth, 1.5x IPM growth, hopefully, we sho ew years. our pain management therapy would be in the overall business? ere the largest product would be Zerodol and if I'm not wron 50 crores, INR800 crores... at, the pain therapy has grown by 14% in the 9 months of the g out how big is Zerodol for us at this moment?
SKUs are amongst the top 300 selling -- 3 SKUs, top 300 sel you expecting pain management to stay at almost like at 13%, 1 ell? Is it possible to...
of R&D cost. That han Mutual Fund. s at Ipca level that were not booked, ve been booked in ne of Bharat from ss. So how do you rs, if you talk a bit ould continue with ? ng that product is e current financial lling brands in the 14% growth going
Yes, definitel growth. So th But what is dr growth will b will be also looking to ma Let's say, not faster. And if to create enab rheumatologis
So rheumatol 1.5x the mark down. Signifi corner of the c
And as far as it is growing we don't see pace.
So we are no concerned, th side, yes, ther on everything continue to ad
So we -- and which we are the -- particul we will -- we faster than the And every ma higher than th Okay. Sure. T Thank you. A over to the ma No, more or anything furth
Fe Page 18 of 19 ly, unless pain management grows 13%, 14%, I can't grow at is almost 52% of my overall business. riving this growth in the overall pain management? If you could be maintained? Because we'll be covering large part of the mar one of the foremost when it comes to the pain management aintain this growth going forward as well? t only osteoarthritis product, but rheumatoid arthritis products f more penetration of disease presence in the country is very hi bling more number of rheumatologists practicing in the market st to the other areas and educating doctors and all. logy portfolio, is last 10, 15 years, also, we have seen continu ket growth. And we don't foresee next 5 years also that grow icant work is still to be done to make all these therapies availabl country. the pain is concerned, Zerodol is continuously growing. Even in faster than the overall IPM, it's almost around 1.5x the marke any kind of problem in growing this therapy also in next 3, ot seeing any kind of challenge. And as far as the new prod here are not much on particularly on osteoarthritis side. On rh re are a lot of opportunities and of the new patented products, an g of that. So we are keeping our complete hold on that kind of th dd the new product portfolios as and when the patent expiry hap also, we are further augmenting our ortho offering by addition e currently in the process of doing that so that we can leverage larly in ortho segment. So that segment will continue to remain don't foresee any kind of difficulty in growing this business. In e overall company growth. ajor product I'm selling in pain category, I'm the market leader he market growth. Thanks a lot, sir.
As there are no further questions from the participants, I will ha anagement for closing comments. Over to you, sir. less most of the areas we have covered in the con call. I do her to be added. Thank you. Thank you all the participants. Than
w 1.5x the market d talk and how this rket, doctor access t. So how we are are also growing gh. It's all we had t and taking those ously it's growing wth rate can come le in any nook and n this market, also et is growing. And 4 years at current duct offerings are heumatoid arthritis nd we are working hings, and we will ppens and all. n of new divisions, those relations in n focus for us, and n fact, it will grow and my growth is and the conference on't think there is nk you very much.
Thank you, si Thank you for
Fe Page 19 of 19 ir. On behalf of DAM Capital Advisors Limited, that conclude r joining us, and you may now disconnect your lines. Thank you
es this conference. u.